Edward Faber, DO on Results of the ENDURANCE Phase III Trial #ASCO2020 #ASCO

Edward Faber, DO on Results of the ENDURANCE Phase III Trial #ASCO2020 #ASCO

User Photo
Cancer-News

4 months
41 Views
Share
Want to watch this again later?
Sign in to add this video to a playlist. Login
0 1
Category:
Description:

Edward A. Faber, DO, MS on carfilzomib, lenalidomide, and dexamethasone vs. bortezomib, lenalidomide, and dexamethasone for initial therapy of newly diagnosed multiple myeloma: results of ENDURANCE (E1A11) phase III trial.

Read here: https://meetinglibrary.asco.org/record/186906/abstract

Up Next Autoplay
>